60 results
In accordance with its mandate to provide guidance to Member States on health policy matters, WHO publishes vaccine position papers providing global vaccine and immunization recommendations for...
COSTVAC is an Excel-based toolkit that provides structured guidance on how to estimate the cost of routine immunization from a sample of health facilities and administrative levels of the health...
The WHO website provides a list of certain diseases for which vaccines are available, and a list of some pathogens for which vaccines and/or monoclonal antibodies (mAbs) are in development. For each...
UNIVAC is a single universal vaccine impact and cost-effectiveness decision support model with a standardized, accessible Excel-based (now based in R), interface and a familiar set of input steps and...
The Consortium aims to deliver a more sustainable, efficent, and transparent approach to generating disease burden and vaccine impact estimates. It works on aggregating the estimates across a...
The MenAfriVac CTC experience in Benin: English version
The meningitis road map has been designated as a flagship global strategy of the WHO’s Thirteenth General Programme of Work, 2019–2023 and is an essential component in achieving universal health...
La méningite est mortelle et débilitante ; elle frappe brutalement ; elle a de graves conséquences sanitaires, économiques et sociales et touche tous les âges de la vie dans tous les pays du...
Despite advances in the development and introduction of vaccines against the major bacterial causes of meningitis, the disease and its long-term after-effects remain a problem globally. The Global...
In accordance with its mandate to provide
guidance to Member States on health policy
matters, WHO issues a series of regularly
updated position papers on vaccines
and combinations of vaccines...
Until recently, most meningitis epidemics in the meningitis belt of sub-Saharan Africa were due to Neisseria meningitidis serogroup A (NmA), such that the existing WHO guidelines have been directed...
This document aims to provide standardized guidance for public health authorities and investigators at all levels to plan and conduct the investigation of every meningitis case of Nm A. This...
Since 2010, the Neisseria meningitidis (Nm) A conjugate vaccine is being introduced on a large scale in countries of the African meningitis belt. It is expected that this vaccination programme will...
Household contacts of an index case of invasive meningococcal disease (IMD) are at increased risk of acquiring disease. In revising WHO guidance on IMD in sub-Saharan Africa, a systematic review was...
An economic evaluation of the controlled temperature
chain approach for vaccine logistics: evidence from a study
conducted during a meningitis A vaccine campaign in Togo
Utilisation du MenAfriVac™ (vaccin contre la méningite A) en chaîne à températtrôlée (CTC) pendant les campagnes - Guide d\'adaptation et guide du formateur
Utilisation du MenAfriVac™ (vaccin contre la méningite A) en chaîne à température contrôlée (CTC) pendant les campagnes - Module de formation pour l\'organisation de séances de vaccination
To summarize and critically evaluate the evidence on the impact and effectiveness of meningococcal vaccination programs around the world in order to inform decision-making in Latin America and the...
As of May 2017, two medical laboratory scientists employed by the Sokoto State Government, jointly trained by the University of Nebraska Medical Centre and eHA are operating the lab. During the 2017...
This fact sheet describes PATH’s efforts to eliminate meningococcal meningitis epidemics from Africa, once and for all. It covers work across meningitis projects, including the development and...
Background: In preparation for the introduction of MenAfriVac, a meningococcal group A conjugate vaccine developed for the African meningitis belt, an enhanced meningitis surveillance network was...
BACKGROUND: Routine infant immunization with meningococcal C conjugate (MCC) vaccination started in Brazil in November 2010, scheduled at three and five months plus a booster at 12-15months of age....
Background: Limited data are available describing the post-licensure safety of meningococcal vaccines, including Menveo®. We reviewed reports of adverse events (AEs) to the Vaccine Adverse Event...
BACKGROUND: Meningococcal conjugate vaccination is recommended in the United States. This study evaluates the safety of quadrivalent meningococcal conjugate vaccine in a cohort aged 11 to 21 years....
Background
Bivalent rLP2086 is a recombinant factor H binding protein-based vaccine approved in the USA for prevention of meningococcal serogroup B disease in 10–25-year-olds. We aimed to assess...
Background
In September, 2015, the UK became the first country to introduce the multicomponent group B meningococcal (MenB) vaccine (4CMenB, Bexsero) into a publicly funded national immunisation...
The Global Meningococcal Initiative (GMI) is a global expert group that includes scientists, clinicians, and public health officials with a wide range of specialties. The purpose of the Initiative is...
Australia implemented conjugate meningococcal C immunization in
2003 with a single scheduled dose at age 12 months and catch-up for
individuals aged 2–19 years. Several countries have recently...
In October 2012, the Meningococcal A conjugate vaccine MenAfriVac was granted a label variation to allow for its use in a controlled temperature chain (CTC), at temperatures of up to 40 °C for not...
The subject of the present study was a mass campaign against meningitis A that covered three regions of Chad and resulted in the vaccination of 1 807 158 individuals in December 2011. Although 12...
For over 100 years, large epidemics of meningococcal meningitis have occurred every few years in areas of the African Sahel and sub-Sahel known as the African meningitis belt. Until recently, the...
MenAfriVacTM is the first of the World Health Organization (WHO)’s pre-qualified vaccines to be allowed to mass vaccination campaign at a temperature below or equal to 40°C during 4 days. This new...
The individual, societal, and economic benefits of disease prevention resulting from childhood and adult immunization programs in the United States are without question. A report from the Centers for...
Immunogenicity and safety of a new meningococcal A conjugate vaccine in Indian children (2–10 years)
This study compares the immunogenicity and safety of a single dose of a new meningococcal A conjugate vaccine (PsA-TT, MenAfriVac™, Serum Institute of India Ltd., Pune) against the meningococcal...
An affordable, highly immunogenic Neisseria meningitidis serogroup A meningococcal conjugate vaccine (PsA—TT) was licensed for use in sub-Saharan Africa in 2009. In 2010, Burkina Faso became the...
Although rare, invasive meningococcal disease remains an important cause of mortality and morbidity in children and young adults. Vaccines have been successfully introduced to help protect against...
The study sought to develop a method to estimate vaccination coverage using both a computerized vaccine registry with an unknown underreporting rate and a seroprevalence study. A real example of a...
Meningococcal meningitis is a major cause of disease worldwide, with frequent epidemics particularly affecting an area of sub-Saharan Africa known as the “meningitis belt”. Neisseria meningitidis...
BACKGROUND: A new group A meningococcal conjugate vaccine was developed to eliminate deadly meningitis epidemics in sub-Saharan Africa.
METHODS: From the outset of the project, advocacy and...
Although many years of application of meningococcal polysaccharide vaccines have had minimal success in preventing meningococcal epidemics in the meningitis belt of Africa, collaborative efforts to...
Neisseria meningitidis is an important cause of invasive bacterial infection in children worldwide. Although serogroup C meningococcal disease has all but disappeared in the past decade as a direct...
Meningococcal conjugate vaccines protect individuals directly, but can also confer herd protection by interrupting carriage transmission. We assessed the effects of meningococcal quadrivalent...
The study seeks to evaluate the impact of the meningococcal A (MenA) vaccine introduction in Mali through mass campaigns on the routine immunization program and the wider health system.It concludes...
In a multi-center extension study, children 2–10 years of age, initially vaccinated with one or two doses (2–5 year-olds) or one dose (6–10 year-olds) of quadrivalent meningococcal...
The document provides information for
Ministries of Health and hospital sentinel sites on why and how to
determine the denominator of at-risk children <5 years of age
and rate of meningitis...
Mechanisms to increase access to health products are varied and controversial. Two innovative mechanisms have been used to accelerate the development of low-price supply lines for conjugate vaccines....
Recently an investigational meningococcal B vaccine has been used in two college outbreaks in the US. This is the first time that a meningococcal B vaccine has been used for outbreak control in the...
In Italy, the incidence of Invasive Meningococcal Disease (IMD) was around 0.28 per 100,000 over the last years. Since the risk IMD is usually high among infants aged less than 1 year, the...
Vaccines against the polysaccharide meningococcal capsule lead to the prevention of invasive meningococcal diseases due to serotypes A, C, Y, W135. Polysaccharide vaccines, according to their...
Estimation of vaccination coverage at the local level is essential to identify communities that may require additional support. Cluster surveys can be used in resource-poor settings, when population...
A mathematical modelling tool that estimates the impact of scaling up high-impact MNCH and nutrition interventions in low- and middle-income countries. It estimates the impact of these interventions...
To inform epidemic response strategies for the African meningitis belt after a meningococcal serogroup A conjugate vaccine was introduced in 2010, the researchers compared the effectiveness and...
Several outbreaks caused by Neisseria meningitidis group C have been occurred in different regions of Brazil. A conjugate vaccine for Neisseria meningitidis was produced by chemical linkage between...
WHO and PATH, through the Optimize project, have developed a training module for training of nurses and other health workers organizing immunization sessions on how to use the CTC. This guide...
By working through this module, you will learn how to integrate controlled temperature chain (CTC) into your regular immunization sessions during an immunization campaign with the Meningitis A...
The need to keep vaccines in a 2°C to 8°C cold chain is a constraining factor for many immunization campaigns due to limited storage capacity and/or limited ice pack freezing capacity;...
BACKGROUND:
To combat Neisseria meningitidis serogroup A epidemics in the meningitis belt of sub-Saharan Africa, a meningococcal serogroup A conjugate vaccine (MACV) has been progressively rolled...
The WHO initiative, Market Information for Access to Vaccines (MI4A) produces vaccine-specific market studies, analyzing global demand and supply prospects for individual vaccines. The studies...